MedTrace Logo

Effect of Eszopiclone on Adherence to CPAP and Severity of Insomnia in Patients With COMISA

NCT06017921 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-03-19

No results posted yet for this study

Summary

The comorbidity between obstructive sleep apnea (OSA) and insomnia (COMISA) is common, and associated with poorer sleep quality. CPAP adherence among COMISA patients is worst than among those with OSA only. The investigators will compare the effect of Eszopiclone 3mg or placebo for 14 days on adherence to CPAP after 30 days and after 6 months.

Conditions

Interventions

DRUG

Eszopiclone 3 mg

Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm

DRUG

Placebo

Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm

Sponsors & Collaborators

  • University of Sao Paulo General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-24
Primary Completion
2025-03-20
Completion
2025-12-20

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06017921 on ClinicalTrials.gov